Nikang Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nikangtx.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Conditions
- HR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid TumorsHR+ HER2- Breast CancerOvarian CancerEndometrial CancerUterine Carcinosarcoma
- Interventions
- Drug: NKT5097 CDK2/CDK4 dual degrader
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- NiKang Therapeutics, Inc.
- Target Recruit Count
- 205
- Registration Number
- NCT07029399
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
🇺🇸South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio, Texas, United States
🇺🇸South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City, Utah, United States
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Conditions
- Solid TumorAdvanced Solid TumorSolid Tumor, AdultMetastatic TumorOvarian CancerOvarian NeoplasmsOvarian CarcinomaMetastatic Ovarian CarcinomaEndometrial NeoplasmsEndometrial Diseases
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- NiKang Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06586957
- Locations
- 🇺🇸
University of Arkansas Medical School, Little Rock, Arkansas, United States
🇺🇸Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study with NKT3447 for Adults with Advanced/Metastatic Solid Tumors
- Conditions
- Ovarian CancerEndometrial CancerEndometrial DiseasesTriple Negative Breast CancerPlatinum-refractory Ovarian CarcinomaHormone Receptor Negative Breast CarcinomaProgesterone-receptor-positive Breast CancerOvarian NeoplasmsOvarian CarcinomaSmall-cell Lung Cancer
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- NiKang Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06264921
- Locations
- 🇺🇸
University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸AdventHealth Cancer Institute, Celebration, Florida, United States
Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
- Conditions
- CcRCCClear Cell Renal Cell CarcinomaKidney CancerKidney NeoplasmsRenal CancerRenal NeoplasmsRecurrent Renal Cell CarcinomaMetastatic Renal Cell CarcinomaRefractory Renal Cell CarcinomaAdvanced Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- NiKang Therapeutics, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT05935748
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma
- Conditions
- CcRCCClear Cell Renal Cell CarcinomaKidney CancerKidney NeoplasmsRenal CancerRenal NeoplasmsRecurrent Renal Cell CarcinomaMetastatic Renal Cell CarcinomaRefractory Renal Cell CarcinomaAdvanced Renal Cell Carcinoma
- Interventions
- Drug: Oral NKT2152
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- NiKang Therapeutics, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT05119335
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute, Denver, Colorado, United States